Plus Therapeutics Highlights Presentation, Says 'Nine of 20 Patients With LM Primary Breast Cancer Were Treated and Evaluable Through Five Dose Escalation Cohorts, With the Maximum Tolerated Dose yet to Be Reached'
Plus Therapeutics Highlights Presentation, Says 'Nine of 20 Patients With LM Primary Breast Cancer Were Treated and Evaluable Through Five Dose Escalation Cohorts, With the Maximum Tolerated Dose yet to Be Reached'
Plus Therapeutics亮點介紹，稱「在20名局部乳腺癌患者中，有9名接受治療並經過評估，尚未達到最大耐受劑量。」
Plus Therapeutics Highlights Presentation, Says 'Nine of 20 Patients With LM Primary Breast Cancer Were Treated and Evaluable Through Five Dose Escalation Cohorts, With the Maximum Tolerated Dose yet to Be Reached'
Plus Therapeutics 亮點演示，表示「20名原發性乳腺癌患者中有9名接受治療並經過五個劑量遞增組評估，尚未達到最大耐受劑量。」
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間